WO2004084859A3 - Nasal calcitonin formulations containing chlorobutanol - Google Patents
Nasal calcitonin formulations containing chlorobutanol Download PDFInfo
- Publication number
- WO2004084859A3 WO2004084859A3 PCT/US2004/008631 US2004008631W WO2004084859A3 WO 2004084859 A3 WO2004084859 A3 WO 2004084859A3 US 2004008631 W US2004008631 W US 2004008631W WO 2004084859 A3 WO2004084859 A3 WO 2004084859A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formulations containing
- calcitonin
- chlorobutanol
- containing chlorobutanol
- calcitonin formulations
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/23—Calcitonins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
Abstract
An aqueous solution of calcitonin suitable for intranasal administration comprised of calcitonin, chlorobutanol at a concentration of less than 0.4% weigh/weigh, and water and having a pH of less than 4 with the proviso that benzalkonium chloride is not present in the solution. The aqueous solution of calcitonin can be used to treat osteoporosis, Paget’s bone disease and hypercalcemia.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US45692103P | 2003-03-21 | 2003-03-21 | |
US60/456,921 | 2003-03-21 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2004084859A2 WO2004084859A2 (en) | 2004-10-07 |
WO2004084859A3 true WO2004084859A3 (en) | 2005-03-03 |
Family
ID=33098172
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2004/008631 WO2004084859A2 (en) | 2003-03-21 | 2004-03-22 | Nasal calcitonin formulations containing chlorobutanol |
Country Status (2)
Country | Link |
---|---|
US (3) | US7812120B2 (en) |
WO (1) | WO2004084859A2 (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004084859A2 (en) * | 2003-03-21 | 2004-10-07 | Nastech Pharmaceutical Company Inc. | Nasal calcitonin formulations containing chlorobutanol |
ITMI20040235A1 (en) * | 2004-02-13 | 2004-05-13 | Therapicon Srl | PHARMACEUTICAL PREPARATION FOR THE ORAL CABLE |
CN103860540A (en) * | 2004-11-24 | 2014-06-18 | 爱尔康公司 | Purpose of preparation of olopatadine for treating nasal allergy or rhinitis |
AU2010313456A1 (en) | 2009-10-30 | 2012-05-17 | Ntf Therapeutics, Inc. | Improved neurturin molecules |
KR101855242B1 (en) | 2012-01-26 | 2018-05-09 | 크리스토퍼 제이. 소레스 | Peptide antagonists of the calcitonin cgrp family of peptide hormones and their use |
WO2017130190A1 (en) * | 2016-01-28 | 2017-08-03 | Ramot At Tel-Aviv University Ltd. | Novel formulation of neuroprotective peptides |
KR102657418B1 (en) | 2016-09-02 | 2024-04-15 | 크리스토퍼 제이 소레스 | Use of CGRP receptor antagonists in neuroprotection and neurological diseases |
CN115920010B (en) * | 2022-09-27 | 2023-09-19 | 深圳大佛药业股份有限公司 | Salmon calcitonin composition spray and preparation method thereof |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2205308A1 (en) * | 1972-11-04 | 1974-05-31 | Hoechst Ag | Luteal hormone-releasing hormone prepns - for treatment of hypothalamus insufficiency by intranasal admin. |
EP0115627A1 (en) * | 1982-12-29 | 1984-08-15 | Armour Pharmaceutical Company | Enhancement of intranasal absorption of calcitonin by formulation with surfactants |
GB2177914A (en) * | 1985-06-04 | 1987-02-04 | Chugai Pharmaceutical Co Ltd | Erythropoietin compositions |
US4670419A (en) * | 1982-07-28 | 1987-06-02 | Takeda Chemical Industries, Ltd. | Pharmaceutical composition and its rectal use |
EP0358234A2 (en) * | 1988-09-08 | 1990-03-14 | Rhone-Poulenc Rorer International (Holdings) Inc. | Intranasal calcitonin formulations |
EP0471618A1 (en) * | 1990-08-16 | 1992-02-19 | Asahi Kasei Kogyo Kabushiki Kaisha | Calcitonin-containing emulsion for nasal administration |
US5482931A (en) * | 1993-06-29 | 1996-01-09 | Ferring Ab | Stabilized pharmaceutical peptide compositions |
US5503827A (en) * | 1991-08-15 | 1996-04-02 | Boehringer Mannheim Gmbh | Process for the production of multi-dose pharmaceutical preparations containing isolated or recombinantly produced human protein for infusion or injection purposes |
US5759565A (en) * | 1982-10-05 | 1998-06-02 | Novartis Corporation | Galenic compositions comprising calcitonin and their use |
Family Cites Families (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ206518A (en) | 1982-12-10 | 1989-06-28 | Syntex Inc | Nasal composition comprising nona- or deca-peptide lhrh analogue and bile acid surfactant |
GB8514090D0 (en) | 1985-06-04 | 1985-07-10 | Sandoz Ltd | Organic compounds |
JPS61267528A (en) | 1984-11-26 | 1986-11-27 | Yamanouchi Pharmaceut Co Ltd | Transnasal calcitonin agent containing absorbefacient |
JPS61194034A (en) | 1985-02-25 | 1986-08-28 | Teijin Ltd | Powdery composition for transnasal administration |
US5179079A (en) | 1986-12-16 | 1993-01-12 | Novo Nordisk A/S | Nasal formulation and intranasal administration therewith |
US5112804A (en) | 1987-04-01 | 1992-05-12 | Temple University Of The Commonwealth System Of Higher Education | Pharmaceutical composition and method of intranasal administration |
US5059587A (en) | 1987-08-03 | 1991-10-22 | Toyo Jozo Company, Ltd. | Physiologically active peptide composition for nasal administration |
DE3726324A1 (en) | 1987-08-07 | 1989-02-16 | Hoechst Ag | CYCLOPEPTIDE AS RESORPTION FOLDER IN APPLICATION TO THE MEAT |
GB8723846D0 (en) | 1987-10-10 | 1987-11-11 | Danbiosyst Ltd | Bioadhesive microsphere drug delivery system |
ES2061688T3 (en) | 1987-11-13 | 1994-12-16 | Smithkline Beecham Farma | PHARMACEUTICAL COMPOSITIONS THAT INCLUDE A CALCITONINE AND A GLICIRRICINATE AS IMPROVER OF ABSORPTION. |
AU629552B2 (en) | 1988-06-16 | 1992-10-08 | Teijin Limited | S-sulfonated calcitonin derivatives |
US5514365A (en) | 1988-10-11 | 1996-05-07 | Schiapparelli Salute S.P.A. | Pharmaceutical compositions comprising calcitonin for intranasal administration |
DK0458894T3 (en) | 1989-02-17 | 1996-10-07 | Liposome Co Inc | Lipid excipients for nasal delivery and topical application |
US5215739A (en) | 1989-04-05 | 1993-06-01 | Toko Yakuhin Kogyo Kabushiki Kaisha | Spray gel base and spray gel preparation using thereof |
JP2514249B2 (en) | 1989-05-23 | 1996-07-10 | 帝人株式会社 | Stabilized calcitonin pharmaceutical composition |
US5725871A (en) | 1989-08-18 | 1998-03-10 | Danbiosyst Uk Limited | Drug delivery compositions comprising lysophosphoglycerolipid |
IT1231957B (en) | 1989-09-15 | 1992-01-16 | Esseti Chimico Farmaco Bio | STABLE PHARMACEUTICAL COMPOSITIONS BASED ON CALCITONIN. |
EP0432431B1 (en) | 1989-11-16 | 1993-06-16 | PHIDEA S.p.A. | Liquid pharmaceutical composition for nasal administration containing a polypeptide as active ingredient |
NZ236618A (en) | 1990-01-03 | 1997-06-24 | Ciba Geigy Ag | Treating and preventing osteoporosis using insulin-like growth factor i (igf i) in conjunction with a bone antiresorptive active compound |
AU7880991A (en) | 1990-05-10 | 1991-11-27 | Novo Nordisk A/S | A pharmaceutical preparation containing n-glycofurols and n-ethylene glycols |
US6221367B1 (en) | 1992-06-15 | 2001-04-24 | Emisphere Technologies, Inc. | Active agent transport systems |
CA2050425A1 (en) | 1990-09-03 | 1992-03-04 | Yoshiaki Uda | Pharmaceutical composition and its mucous use |
FR2668490B1 (en) | 1990-10-29 | 1994-04-29 | Elf Aquitaine | SCLEROGLUCANE GEL APPLIES TO THE OIL INDUSTRY. |
EP0489217A1 (en) | 1990-12-05 | 1992-06-10 | Dr. A. Tosi Farmaceutici S.R.L. | Calcitonin compositions for intranasal administration |
US5527771A (en) | 1991-01-10 | 1996-06-18 | Amylin Pharmaceuticals, Inc. | Methods and Compositions for treatment of diabetes mellitus, hypoglycemia & other conditions |
US5321008A (en) | 1991-01-10 | 1994-06-14 | Amylin Pharmaceuticals, Inc. | Methods and compositions for treatment of diabetes mellitus, hypoglycemia, and other conditions |
EP0566135A1 (en) | 1992-04-17 | 1993-10-20 | Takeda Chemical Industries, Ltd. | Transmucosal composition comprising a peptide and a cytidine derivative |
TW274552B (en) | 1992-05-26 | 1996-04-21 | Hoechst Ag | |
US5654000A (en) | 1992-07-28 | 1997-08-05 | Poli Industria Chimica S.P.A. | Pharmaceutical compositions for transmucosal delivery of peptides |
IT1255895B (en) | 1992-10-20 | 1995-11-17 | Laura Chiodini | PHARMACEUTICAL COMPOSITIONS CONTAINING A CALCITONIN |
US5681811A (en) | 1993-05-10 | 1997-10-28 | Protein Delivery, Inc. | Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same |
US5576016A (en) | 1993-05-18 | 1996-11-19 | Pharmos Corporation | Solid fat nanoemulsions as drug delivery vehicles |
DE69430295T2 (en) | 1993-07-30 | 2002-10-31 | Teijin Ltd | Powder for nasal administration of peptide or protein drugs |
JPH07165613A (en) | 1993-10-19 | 1995-06-27 | Dot:Kk | Carrier for nasal absorption medicine and physiologically active peptide composition |
JP3414539B2 (en) | 1994-05-11 | 2003-06-09 | 有限会社ドット | Composition for nasal absorption |
AU689359B2 (en) | 1994-12-28 | 1998-03-26 | Teikoku Hormone Mfg. Co., Ltd. | Transmucosal preparation |
EP0726075A1 (en) | 1995-02-08 | 1996-08-14 | Therapicon Srl | Pharmaceutical non-inorganic saline solutions for endonasal administration |
WO1997031626A1 (en) | 1996-02-27 | 1997-09-04 | Teijin Limited | Powdery composition for nasal administration |
EP0821975A1 (en) | 1996-07-31 | 1998-02-04 | Novartis AG (Novartis SA) (Novartis Inc.) | Dosing device for fluids |
JP3020141B2 (en) | 1996-10-07 | 2000-03-15 | 株式会社富士薬品 | Formulation for nasal administration |
US7303768B2 (en) | 1998-07-24 | 2007-12-04 | Seo Hong Yoo | Preparation of aqueous clear solution dosage forms with bile acids |
US6428814B1 (en) | 1999-10-08 | 2002-08-06 | Elan Pharma International Ltd. | Bioadhesive nanoparticulate compositions having cationic surface stabilizers |
US6149893A (en) | 1999-03-01 | 2000-11-21 | Alfa Wassermann S.P.A. | Pharmaceutical compositions containing calcitonin in a spray dosing feeder for intranasal administration |
AU6646500A (en) | 1999-08-17 | 2001-03-13 | Image Therm Engineering | Spray data analysis and characterization system |
US6382204B1 (en) | 1999-10-14 | 2002-05-07 | Becton Dickinson And Company | Drug delivery system including holder and drug container |
US6720001B2 (en) | 1999-10-18 | 2004-04-13 | Lipocine, Inc. | Emulsion compositions for polyfunctional active ingredients |
US6998137B2 (en) | 2000-04-07 | 2006-02-14 | Macromed, Inc. | Proteins deposited onto sparingly soluble biocompatible particles for controlled protein release into a biological environment from a polymer matrix |
US6589549B2 (en) | 2000-04-27 | 2003-07-08 | Macromed, Incorporated | Bioactive agent delivering system comprised of microparticles within a biodegradable to improve release profiles |
EP1326630B1 (en) | 2000-09-18 | 2008-05-28 | Sanos Bioscience A/S | Use of glp-2 peptides |
US6544497B2 (en) | 2001-02-15 | 2003-04-08 | Aeropharm Technology Incorporated | Modulated release particles for aerosol delivery |
US6485707B2 (en) | 2001-02-15 | 2002-11-26 | Aeropharm Technology Incorporated | Modulated release particles for aerosol delivery |
US6551578B2 (en) | 2001-02-15 | 2003-04-22 | Aeropharm Technology Incorporated | Modulated release particles for aerosol delivery |
WO2003000429A2 (en) | 2001-06-21 | 2003-01-03 | Image Therm Engineering, Inc. | Precise position controlled actuating method and system |
WO2004084859A2 (en) | 2003-03-21 | 2004-10-07 | Nastech Pharmaceutical Company Inc. | Nasal calcitonin formulations containing chlorobutanol |
-
2004
- 2004-03-22 WO PCT/US2004/008631 patent/WO2004084859A2/en active Search and Examination
- 2004-03-22 US US10/805,788 patent/US7812120B2/en active Active
-
2010
- 2010-09-09 US US12/878,936 patent/US8138149B2/en not_active Expired - Lifetime
-
2012
- 2012-02-10 US US13/371,037 patent/US8486891B2/en not_active Expired - Lifetime
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2205308A1 (en) * | 1972-11-04 | 1974-05-31 | Hoechst Ag | Luteal hormone-releasing hormone prepns - for treatment of hypothalamus insufficiency by intranasal admin. |
US4670419A (en) * | 1982-07-28 | 1987-06-02 | Takeda Chemical Industries, Ltd. | Pharmaceutical composition and its rectal use |
US5759565A (en) * | 1982-10-05 | 1998-06-02 | Novartis Corporation | Galenic compositions comprising calcitonin and their use |
EP0115627A1 (en) * | 1982-12-29 | 1984-08-15 | Armour Pharmaceutical Company | Enhancement of intranasal absorption of calcitonin by formulation with surfactants |
GB2177914A (en) * | 1985-06-04 | 1987-02-04 | Chugai Pharmaceutical Co Ltd | Erythropoietin compositions |
EP0358234A2 (en) * | 1988-09-08 | 1990-03-14 | Rhone-Poulenc Rorer International (Holdings) Inc. | Intranasal calcitonin formulations |
EP0471618A1 (en) * | 1990-08-16 | 1992-02-19 | Asahi Kasei Kogyo Kabushiki Kaisha | Calcitonin-containing emulsion for nasal administration |
US5503827A (en) * | 1991-08-15 | 1996-04-02 | Boehringer Mannheim Gmbh | Process for the production of multi-dose pharmaceutical preparations containing isolated or recombinantly produced human protein for infusion or injection purposes |
US5482931A (en) * | 1993-06-29 | 1996-01-09 | Ferring Ab | Stabilized pharmaceutical peptide compositions |
Also Published As
Publication number | Publication date |
---|---|
US8486891B2 (en) | 2013-07-16 |
US7812120B2 (en) | 2010-10-12 |
WO2004084859A2 (en) | 2004-10-07 |
US20040224890A1 (en) | 2004-11-11 |
US20120142592A1 (en) | 2012-06-07 |
US20110009321A1 (en) | 2011-01-13 |
US8138149B2 (en) | 2012-03-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2005110448A3 (en) | Nutritional composition for increasing creatine uptake in skeletal muscle | |
MY153718A (en) | Formulation of human antibodies for treating tnf-(?) associated disorders | |
MXPA03006841A (en) | 4-fluoro-n-indan-2-yl benzamide and its use as pharmaceutical. | |
NO331024B1 (en) | Use of risendronic acid for the prevention or treatment of osteoporosis | |
WO2004084859A3 (en) | Nasal calcitonin formulations containing chlorobutanol | |
UA87506C2 (en) | Use of electrolyte as inhibitor stabilizer | |
TW326028B (en) | A novel physiologically active substance | |
HK1079431A1 (en) | Zoledronic acid for preventing or reducing secondary fractures after hip fracture | |
BRPI0410116A (en) | oral care tablet | |
UA86007C2 (en) | Agent for stabilization of bio-diesel fuel | |
AR035266A1 (en) | DISINFECTANT SOLUTION BASED ON SODIUM HYPOCHLORITE AND PROCEDURE FOR PREPARATION | |
PT1255557E (en) | PREPARATION OF PHARMACEUTICAL STABILITY OF NASAL ORAL OR SUB-LINGUAL APPLICATION CONTAINING DESMOPRESSIN | |
UA83737C2 (en) | Method for reducing the cyanide levels in a mesotrione sample | |
DZ3269A1 (en) | PHARMACEUTICAL COMPOSITION COMPRISING PEMETREXED WITH MONOTHIOGLYCEROL, CYSTEIN L OR THIOGLYCOLIC ACID | |
BR9909357A (en) | Mirtazapine solution or suspension mixed with water, pharmaceutical formulation comprising mirtazapine, and use of mirtazapine | |
WO2003107400A3 (en) | Acid etching mixture having reduced water content | |
DE60316010D1 (en) | NEW CRYSTALLINE HYDRATES OF THE SODIUM SALT OF 3-PYRIDYL-1-HYDROXYETHYLIDE-1-BISPHOSPHONIC ACID | |
SI0875248T1 (en) | Use of hyaluronic acid for the preparation of an aqueous solution useful as intra-articular lavage liquid | |
PL1663141T3 (en) | Aqueous pharmaceutical solution containing oxymetazoline and/or xylometazoline | |
SI1543826T1 (en) | Concentrated aqueous solution of ambroxol | |
MY136546A (en) | A pharmaceutical component based on human parathyroid harmone and a pharmaceutical composition for intranasal administration comprising the component | |
WO2003094905A8 (en) | Diclofenac-based composition for the topical treatment of oropharyngeal cavity disorders | |
HK1068863A1 (en) | Method for producing an essentially chlorite-free,stable, aqueous chlorine-oxygen solution, the chl orine-oxygen solution obtained by means of said method, and the use of the same | |
TWI265376B (en) | Positive resist composition | |
EP1552838A4 (en) | Rubrofusarin glycoside-containing composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DPEN | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101) | ||
122 | Ep: pct application non-entry in european phase | ||
DPE2 | Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101) |